BiotechTube

mRNA-1083 Composition 1 Dose A Lot A

Phase 2Completed
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza, SARS-CoV-2

Conditions

Influenza, SARS-CoV-2

Trial Timeline

Mar 7, 2025 → Oct 13, 2025

NCT ID
NCT06864143

About mRNA-1083 Composition 1 Dose A Lot A

mRNA-1083 Composition 1 Dose A Lot A is a phase 2 stage product being developed by Moderna for Influenza, SARS-CoV-2. The current trial status is completed. This product is registered under clinical trial identifier NCT06864143. Target conditions include Influenza, SARS-CoV-2.

What happened to similar drugs?

20 of 20 similar drugs in Influenza, SARS-CoV-2 were approved

Approved (20) Terminated (1) Active (0)
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
✅Trivalent Influenza Virus VaccineAstraZenecaApproved
✅Vaxelis + PedvaxHIBMerckApproved

Clinical Trials (1)

NCT IDPhaseStatus
NCT06864143Phase 2Completed

Competing Products

20 competing products in Influenza, SARS-CoV-2

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1018 for H5N8ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0